THERANEXUSTHERANEXUSTHERANEXUS

THERANEXUS

No trades
See on Supercharts
Market capitalization
‪4.47 M‬EUR
−0.400EUR
‪−6.83 M‬EUR
0.00EUR
‪4.25 M‬
Beta (1Y)
0.22

About THERANEXUS


CEO
Mathieu Bernard Mari Charveriat
Headquarters
Lyon
Founded
2013
ISIN
FR0013286259
FIGI
BBG00HYCJ4F3
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. It offers psychotropic drugs for the treatment of neurological disorders such as narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain, psychiatric conditions, and epilepsy. The company was founded by Franck Joseph Louis Mouthon and Mathieu Bernard Mari Charveriat on March 19, 2013 and is headquartered in Lyon, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ALTHX is 0.572 EUR — it has decreased by −0.34% in the past 24 hours. Watch THERANEXUS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange THERANEXUS stocks are traded under the ticker ALTHX.
ALTHX stock has fallen by −2.36% compared to the previous week, the month change is a 15.14% rise, over the last year THERANEXUS has showed a −50.00% decrease.
We've gathered analysts' opinions on THERANEXUS future price: according to them, ALTHX price has a max estimate of 6.20 EUR and a min estimate of 6.20 EUR. Watch ALTHX chart and read a more detailed THERANEXUS stock forecast: see what analysts think of THERANEXUS and suggest that you do with its stocks.
ALTHX reached its all-time high on Jan 18, 2021 with the price of 23.600 EUR, and its all-time low was 0.460 EUR and was reached on Nov 12, 2024. View more price dynamics on ALTHX chart.
See other stocks reaching their highest and lowest prices.
ALTHX stock is 4.98% volatile and has beta coefficient of 0.22. Track THERANEXUS stock price on the chart and check out the list of the most volatile stocks — is THERANEXUS there?
Today THERANEXUS has the market capitalization of ‪4.44 M‬, it has decreased by −9.09% over the last week.
Yes, you can track THERANEXUS financials in yearly and quarterly reports right on TradingView.
ALTHX net income for the last half-year is ‪100.80 K‬ EUR, while the previous report showed ‪−3.18 M‬ EUR of net income which accounts for 103.17% change. Track more THERANEXUS financial stats to get the full picture.
No, ALTHX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALTHX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade THERANEXUS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So THERANEXUS technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating THERANEXUS stock shows the sell signal. See more of THERANEXUS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.